We narrowed to 131 results for: egf

#202199-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE (#202199). In addition to the viral particles, you will also receive purified pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of bicistronically soma-targeted ChrimsonR in frame with EGFP and the optimized opsin PdCO. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#214853-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14035: pAAV-AiE0452h_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4035) (#214853). In addition to the viral particles, you will also receive purified AiP14035: pAAV-AiE0452h_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4035) plasmid DNA. minBG-driven expression of CoChR-EGFP striatal indirect pathway medium spiny neurons (D2 MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#198513-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#112677-AAV2

Ready-to-use AAV2 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Jan. 17, 2020

Academic Institutions and Nonprofits only

#50465-AAV11

Ready-to-use AAV11 particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 16, 2025

Academic Institutions and Nonprofits only

#214852-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14033: pAAV-AiE0779m_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4033) (#214852). In addition to the viral particles, you will also receive purified AiP14033: pAAV-AiE0779m_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4033) plasmid DNA. minBG-driven expression of CoChR-EGFP in striatal direct pathway medium spiny neurons (D1 MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#202199-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE (#202199). In addition to the viral particles, you will also receive purified pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of bicistronically soma-targeted ChrimsonR in frame with EGFP and the optimized opsin PdCO. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#50465-AAV11.T

Ready-to-use AAV11 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 16, 2025

Academic Institutions and Nonprofits only

#79871-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO_EGFP-GFE3 (#79871). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO_EGFP-GFE3 plasmid DNA. EF1a-driven, Cre-dependent expression of GFP-GFE3. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Gross et al Nat Methods. 2016 Jun 6. doi: 10.1038/nm

Nov. 13, 2025

Academic Institutions and Nonprofits only

#138327-AAV1

Ready-to-use AAV1 particles produced from pAAV-synapsin-HaloCaMP1a-EGFP (#138327). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1a-EGFP plasmid DNA. Synapsin-driven HaloCaMP1a, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only

#65453-AAV1

Ready-to-use AAV1 particles produced from AAV pTRE-FSF-FLEX-EGFP-WPRE-bGHpA (#65453). In addition to the viral particles, you will also receive purified AAV pTRE-FSF-FLEX-EGFP-WPRE-bGHpA plasmid DNA. TRE-driven, Cre and Flp-dependent expression of EGFP. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

Feb. 14, 2022

Academic Institutions and Nonprofits only

#190155-AAV8

Ready-to-use AAV8 particles produced from AAV_pMBP-EGFP-caax (#190155). In addition to the viral particles, you will also receive purified AAV_pMBP-EGFP-caax plasmid DNA. MBP-driven EGFP expression in oligodendrocytes. These AAV preparations are suitable purity for injection into animals.

Brad Zuchero

Lam et al Nat Commun. 2022 Sep 23;13(1):5583. doi:

Feb. 6, 2026

Academic Institutions and Nonprofits only

#214869-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP15140: pAAV-AiE0873m_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN5140) (#214869). In addition to the viral particles, you will also receive purified AiP15140: pAAV-AiE0873m_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN5140) plasmid DNA. minBG-driven expression of CoChR-EGFP in striatal cholinergic neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#138328-AAV1

Ready-to-use AAV1 particles produced from pAAV-synapsin-HaloCaMP1b-EGFP (#138328). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1b-EGFP plasmid DNA. Synapsin-driven HaloCaMP1b, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only

#221463-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_eGFP (#221463). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_eGFP plasmid DNA. Expression of EGFP under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#105542-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.CB7.CI.eGFP.WPRE.rBG (#105542). In addition to the viral particles, you will also receive purified pENN.AAV.CB7.CI.eGFP.WPRE.rBG plasmid DNA. CB7-driven eGFP. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 24, 2018

Academic Institutions and Nonprofits only

#203847-AAV2

Ready-to-use AAV2 particles produced from pAAV-Ef1a-fDIO-rc[Chronos-eGFP]-WPRE (#203847). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-rc[Chronos-eGFP]-WPRE plasmid DNA. Ef1a-driven, Flp-dependent expression of Chronos-EGFP. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Cohen-Kashi Malina et al Neuron. 2021 Jul 7;109(13):2150-2164.e5.

Jan. 15, 2026

Academic Institutions and Nonprofits only

#190155-AAV1

Ready-to-use AAV1 particles produced from AAV_pMBP-EGFP-caax (#190155). In addition to the viral particles, you will also receive purified AAV_pMBP-EGFP-caax plasmid DNA. MBP-driven EGFP expression in oligodendrocytes. These AAV preparations are suitable purity for injection into animals.

Brad Zuchero

Lam et al Nat Commun. 2022 Sep 23;13(1):5583. doi:

Jan. 15, 2026

Academic Institutions and Nonprofits only

#221463-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_eGFP (#221463). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_eGFP plasmid DNA. Expression of EGFP under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#138328-AAV9

Ready-to-use AAV9 particles produced from pAAV-synapsin-HaloCaMP1b-EGFP (#138328). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1b-EGFP plasmid DNA. Synapsin-driven HaloCaMP1b, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only